At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
bimatoprost 0.03%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
In Brief
A Phase 4 clinical trial evaluating bimatoprost 0.03% for Eyelash Hypotrichosis. Completed, enrolled 62 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyelash Hypotrichosis
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
Primary CompletionJun 2010
Study CompletionOct 2010
First PostedOct 2010
TodayJul 2026
First PostedOct 27, 2010
Enrollment StartNov 1, 2009
Primary CompletionJun 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.7 years ago
Interventions
bimatoprost 0.03%drug
One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.